Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation site inhibitor YY201 successfully completed dual submissions in China and US

Recently, YY201, a STAT3 dual phosphorylation site inhibitor independently developed by Yuyao Biotech, was approved by the US FDA and agreed to conduct Phase I clinical studies for malignant hematological tumors. This is another milestone after YY201 IND was approved by China's NMPA in July 2023. It is also an important step for Yuyao Biotech to move towards globalization and international development with its independently built first-class technology platform and leading product pipeline.

Learn more about Medicilon's STAT3-targeted Drugs R&D Services.

Yuyao Biotech.webp

Shanghai Medicilon Inc. (Medicilon), as a partner of Yuyao Biotech, provided YY201 with pharmaceutical research services (including APIs and preparations), preclinical research services (including efficacy, pharmacokinetics, safety evaluation), and IND application services, which helped YY201 successfully complete dual submissions in China and US.

Tackle the most cutting-edge new drug research and development technologies

Medicilon continues to iterate its one-stop preclinical R&D service platform

Innovate technology ahead of clients and lay out plans ahead of industry needs. In the past two decades, Medicilon has continued to increase investment in R&D, focusing on cutting-edge fields such as nucleic acid drugs, cellular immunity, mRNA vaccines, PROTAC, ADC, and bi/multi-specific antibodies, building an innovative R&D service platform, and continuing to iterate and update, to help more "First-in-class" drugs successfully enter clinical trial and achieve dual approval in China and US.

About Yuyao Biotech

Yuyao Biotechnology is a new drug research and development enterprise empowered by AI, led by innovation, and focusing on new technologies and new targets. The company has three world-class new drug research and development platforms and multiple independent original product pipelines, and the core products are currently undergoing clinical research registration. The product pipeline, YY001, targets the tumor immune microenvironment to treat PD-1 antibody-sensitive and insensitive advanced solid tumors, is about to start Phase 2 clinical research and has the potential to become the world's best immune microenvironment antagonist. The product YY201 is the world's first transcription factor inhibitor, which is about to start phase 1 clinical research in China and the United States, and other product pipelines will soon enter clinical trials in the future. The company has applied for more than 20 invention patents and has entered Europe, the United States, Japan, Canada, and Australia through PCT international applications.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 385 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

Shanghai Medicilon Inc.

搜索此博客